BBA MD - Fluoguide Chief Officer
FLUO Stock | SEK 39.90 3.00 8.13% |
Insider
BBA MD is Chief Officer of Fluoguide AS
Age | 58 |
Phone | 45 31 22 66 60 |
Web | https://fluoguide.com |
Fluoguide Management Efficiency
The company has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5643) %, meaning that it generated substantial loss on money invested by shareholders. Fluoguide's management efficiency ratios could be used to measure how well Fluoguide manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Katja Margell | Hansa Biopharma AB | N/A | |
Anthony Pare | BioPorto | 60 | |
Klaus Sindahl | Hansa Biopharma AB | N/A | |
Tony Summerlin | cBrain AS | N/A | |
Neil CPA | BioPorto | 55 | |
Nis Kruse | BioPorto | N/A | |
Jennifer Zonderman | BioPorto | N/A | |
Lars Petersen | ExpreS2ion Biotech Holding | N/A | |
Niels Kristensen | cBrain AS | N/A | |
Mattis Ranthe | ExpreS2ion Biotech Holding | N/A | |
Keith Alexander | ExpreS2ion Biotech Holding | N/A | |
Emanuel Bjrne | Hansa Biopharma AB | 50 | |
Christopher Bird | BioPorto | N/A | |
Mette Thorn | ExpreS2ion Biotech Holding | N/A | |
Max Sogaard | ExpreS2ion Biotech Holding | N/A | |
Ejvindgensen | cBrain AS | N/A | |
Lars Uttenthal | BioPorto | N/A | |
Bent MSc | ExpreS2ion Biotech Holding | N/A | |
Anne Lanner | Hansa Biopharma AB | 54 | |
Gry Larsen | BioPorto | N/A | |
Sren MSc | Hansa Biopharma AB | 58 |
Management Performance
Return On Equity | -0.56 | |||
Return On Asset | -0.38 |
Fluoguide AS Leadership Team
Elected by the shareholders, the Fluoguide's board of directors comprises two types of representatives: Fluoguide inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fluoguide. The board's role is to monitor Fluoguide's management team and ensure that shareholders' interests are well served. Fluoguide's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fluoguide's outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MSc, CMO, CSO | ||
BBA MD, Chief Officer | ||
Henrik Hang, Chief Officer | ||
Grethe MSc, Chief Officer | ||
Dorthe Mejer, VP Devel |
Fluoguide Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fluoguide a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.56 | |||
Return On Asset | -0.38 | |||
Current Valuation | 497.47 M | |||
Shares Outstanding | 11.81 M | |||
Shares Owned By Insiders | 42.46 % | |||
Shares Owned By Institutions | 9.27 % | |||
Price To Book | 8.86 X | |||
Price To Sales | 348.55 X | |||
EBITDA | (28.9 M) | |||
Net Income | (23.77 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fluoguide Stock Analysis
When running Fluoguide's price analysis, check to measure Fluoguide's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fluoguide is operating at the current time. Most of Fluoguide's value examination focuses on studying past and present price action to predict the probability of Fluoguide's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fluoguide's price. Additionally, you may evaluate how the addition of Fluoguide to your portfolios can decrease your overall portfolio volatility.